Background Therapy-related AML (t-AML) occurs as a late complication of chemotherapy administered to treat a prior disorder. studies have reported that karyotype is an impartial prognostic parameter in t-AML, these studies focused only on cytogenetic abnormalities and did not include molecular aberrations, Danusertib cytotoxic therapy regimens, or hemograms as prognostic indicators [10-12]. Additionally, a recently… Continue reading Background Therapy-related AML (t-AML) occurs as a late complication of chemotherapy